HPGC Renmintongtai Pharmaceutical Corporation Class A

HPGC Renmintongtai Pharmaceutical Corporation Class A

SSSE:600829
9.69
CNY
-1.08
(-10.03%)
0.27EPS
34.48P/E
5.47BMarket Cap

Total Valuation

CNY

As of September 30, 2026, HPGC Renmintongtai Pharmaceutical Corporation Class A carries a market capitalization of 5.47B, placing it among publicly traded companies globally. Its enterprise value stands at 5.51B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap5.47B
Enterprise Value5.51B

Share Statistics

As of September 30, 2026, HPGC Renmintongtai Pharmaceutical Corporation Class A has 579.89M shares outstanding.

Shares Outstanding579.89M

Valuation Ratios

As of September 30, 2026, HPGC Renmintongtai Pharmaceutical Corporation Class A trades at a trailing price-to-earnings ratio of 34.48. The price-to-sales ratio is 0.51, and the price-to-book ratio stands at 1.74.

PE Ratio34.48
PS Ratio0.51
PB Ratio1.74
P/TBV Ratio1.75

Enterprise Valuation

As of September 30, 2026, HPGC Renmintongtai Pharmaceutical Corporation Class A trades at an EV/EBITDA multiple of 23.49 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.52 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 23.49 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 5.51B versus a market cap of 5.47B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales0.52
EV / EBITDA23.49
EV / EBIT23.49

Financial Position

As of September 30, 2026, HPGC Renmintongtai Pharmaceutical Corporation Class A maintains a current ratio of 1.68, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 22.28, indicating elevated leverage, while an interest coverage ratio of 9.85 demonstrates adequate ability to service its debt obligations.

Current Ratio1.68
Quick Ratio0.16
Debt / Equity22.28
Debt / EBITDA3.00
Interest Coverage9.85

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 3.89M in revenue per employee across its workforce of 2,735.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee3.89M
Employee Count2,735.00

Taxes

CNY

Over the twelve months ended September 30, 2026, HPGC Renmintongtai Pharmaceutical Corporation Class A recorded 65.89M in income tax expense. That works out to an effective tax rate of 29.35, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 224.47M, leaving 158.58M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax65.89M
Effective Tax Rate29.35

Stock Price Statistics

CNY

As of the close on November 17, 2026, HPGC Renmintongtai Pharmaceutical Corporation Class A's stock has declined approximately 41.77% over the past 52 weeks. The 50-day moving average sits at 9.41, while the 200-day moving average is 9.71.

52-Week Price Change-41.77%
50-Day Moving Average9.41
200-Day Moving Average9.71

Income Statement

CNY

Over the twelve months ended September 30, 2026, HPGC Renmintongtai Pharmaceutical Corporation Class A generated 10.64B in revenue and converted that into 158.58M in net income, yielding earnings per share of 0.27. EBITDA reached 234.43M, while operating income came in at 307.07M.

Revenue10.64B
Gross Profit894.59M
Operating Income307.07M
Pretax Income224.47M
Net Income158.58M
EBITDA234.43M
EBIT234.43M
Earnings Per Share (EPS)0.27

Balance Sheet

CNY

As of September 30, 2026, HPGC Renmintongtai Pharmaceutical Corporation Class A holds 663.44M in cash and equivalents against 702.20M in total debt, resulting in a net debt position of -24.04M. Total book value stands at 3.15B, with working capital of 2.79B providing operational flexibility.

Cash & Cash Equivalents663.44M
Total Debt702.20M
Net Debt-24.04M
Equity (Book Value)3.15B
Book Value Per Share5.43
Working Capital2.79B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-28.33M

Margins

Over the twelve months ended September 30, 2026, HPGC Renmintongtai Pharmaceutical Corporation Class A posted a gross margin of 8.41, reflecting its pricing power and cost economics. The operating margin of 2.89 and net profit margin of 1.49 provide insight into operational efficiency.

Gross Margin8.41
Operating Margin2.89
Pretax Margin2.11
Profit Margin1.49
EBITDA Margin2.20

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, HPGC Renmintongtai Pharmaceutical Corporation Class A paid dividends of 0.03 per share. The dividend payout ratio of 11.10 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 2.03, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to HPGC Renmintongtai Pharmaceutical Corporation Class A shareholders.

Dividend Per Share0.03
Payout Ratio11.10
Shareholder Yield2.03

Stock Splits

HPGC Renmintongtai Pharmaceutical Corporation Class A's most recent stock split took place on June 14, 2011 with a 2:3 split ratio.

Last Split Date6/14/2011
Split Ratio2:3

Scores

As of September 30, 2026, HPGC Renmintongtai Pharmaceutical Corporation Class A has an Altman Z-Score of 3.27, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.27